Co-founder Tushar Patel's stake rises to 17.6% after Kashiv Acquisition
AMRX sits 96% above its 52-week low of $8.82.
Summary
Amneal co-founder Tushar Patel's beneficial ownership rose to 17.6% after his entity received 12.76 million shares in the Kashiv BioSciences acquisition, which closed August 10, 2026.
Key Events · Ownership and Investor Activity · AMRX
-
Patel's Stake Rises to 17.6%
Tushar Patel's beneficial ownership increased to 61,341,678 shares (17.6% of Class A common stock) after his entity Rock Nola received 12,763,469 shares in the Kashiv Acquisition.
-
Kashiv Acquisition Closes
The acquisition of Kashiv BioSciences closed on August 10, 2026, with Amneal paying $375 million in cash and issuing 28,942,098 shares to sellers, including Rock Nola.
-
Ownership Consolidation
Patel's increased stake reflects his role as a seller in the acquisition, not a new purchase, consolidating his position as a major shareholder.
Analysis · AMRX · Life Sciences
Tushar Patel, co-founder of Amneal Pharmaceuticals, increased his beneficial ownership to 17.6% (61.3 million shares) after his entity Rock Nola received 12.76 million shares as part of the Kashiv BioSciences acquisition. The deal closed on August 10, 2026, with Amneal paying $375 million in cash and issuing 28.9 million shares to sellers. Patel's increased stake reflects his role as a seller in the acquisition, not a new purchase, and consolidates his position as a major shareholder.
At the time of this filing, AMRX was trading at $17.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.6B. The 52-week trading range was $8.82 to $19.26. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.